Search Results for "ATTRv"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Effect of Patisiran Treatment in Patients with hATTR Amyloidosis with Cardiomyopathy and Polyneuropathy: Post-hoc Analysis of the APOLLO-B Study

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Transition between Patisiran and Vutrisiran

Standard response letter on transitioning between patisiran and vutrisiran therapy.

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

Vutrisiran: Post-Hoc Analysis of HELIOS-A Results by Baseline NIS Quartile

Standard response letter summarizing the results of a post-hoc analysis of the HELIOS-A study, conducted to evaluate the impact of baseline polyneuropathy severity, as measured by NIS, on response to vutrisiran treatment.

Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study

Patisiran: APOLLO Study Results

Standard response letter on patisiran and the APOLLO study, a phase 3 study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.